Data compiled by Redley Lamar · ChainSifter Intelligence
0Suppliers
13Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Beta Bionics, Inc. (BBNX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
2Distinct source URLs
12High confidence
0.827Average confidence
2026-10-29Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Beta Bionics, Inc. Suppliers
No suppliers on recordBeta Bionics, Inc. does not appear to disclose named supplier relationships in its verified regulatory filings, or upstream suppliers have not yet been identified. Our system processes new filings continuously.
Beta Bionics, Inc. Customers
Ticker
Name
Confidence
Evidence
DISTRIBUTOR-A
DISTRIBUTOR-A
92%
Distributor A accounted for 10.4% of net sales and 14.7% of accounts receivable, net for the three months ended March 31, 2026
DISTRIBUTOR-B
DISTRIBUTOR-B
92%
Distributor B accounted for 10.9% of net sales and 13.3% of accounts receivable, net for the three months ended March 31, 2026
DISTRIBUTOR-C
DISTRIBUTOR-C
92%
Distributor C accounted for 14.4% of accounts receivable, net for the three months ended March 31, 2025
DISTRIBUTOR-D
DISTRIBUTOR-D
92%
Distributor D accounted for 11.8% of net sales and 11.6% of accounts receivable, net for the three months ended March 31, 2026
DISTRIBUTOR-E
DISTRIBUTOR-E
92%
Distributor E accounted for 12.0% of accounts receivable, net for the three months ended March 31, 2025
DISTRIBUTOR-F
DISTRIBUTOR-F
92%
Distributor F accounted for 16.9% of accounts receivable, net for the three months ended March 31, 2025
DISTRIBUTOR-G
DISTRIBUTOR-G
92%
Distributor G accounted for 17.8% of net sales and 12.5% of accounts receivable, net for the three months ended March 31, 2026
DISTRIBUTOR-H
DISTRIBUTOR-H
92%
Distributor H accounted for 17.3% of net sales and 19.9% of accounts receivable, net for the three months ended March 31, 2026
ABBOTT-DIABETES-CARE-INC
ABBOTT-DIABETES-CARE-INC
62%
ile application delivers real-time glucose readings, trends and graphs, with data securely stored in the cloud. To maximize the commercial value of the iLet opportunity, we have assembled a team acro…
Reciprocal relationship from ABT graph: Reciprocal relationship from BBNX graph: ile application delivers real-time glucose readings, trends and graphs, with data securely stored in the cloud. To max…
QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY
QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY
62%
cted Volatility—E xpected volatility is derived from the average historical stock volatilities of several public companies within our industry that we consider to be comparable to our business over a…
XERIS-PHARMACEUTICALS-INC
XERIS-PHARMACEUTICALS-INC
62%
ile application delivers real-time glucose readings, trends and graphs, with data securely stored in the cloud. To maximize the commercial value of the iLet opportunity, we have assembled a team acro…
Reciprocal relationship from XERS graph: Reciprocal relationship from BBNX graph: Reciprocal relationship from XERS graph: Reciprocal relationship from BBNX graph: Reciprocal relationship from XERS g…
Beta Bionics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BBNX-DEBT
Debt stack $6.9M
90%
Market cache reports total debt of $6.9M.
BBNX-DEBT-8084
Warrants outstanding: 13000
90%
xbrl warrant detail from xbrl 2025-12-31.
BBNX-DEBT-8085
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Beta Bionics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Beta Bionics, Inc..
Beta Bionics, Inc. Ownership
Holder
Name
Confidence
Evidence
BBNX-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 132 tracked holders.
